ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $15.46 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $11.53 on Wednesday. ARS Pharmaceuticals has a 12-month low of $7.55 and a 12-month high of $18.51. The company has a market capitalization of $1.12 billion, a PE ratio of -22.61 and a beta of 1.03. The firm’s 50-day moving average is $11.98 and its two-hundred day moving average is $13.04.

Insider Buying and Selling

In other news, Director Laura Shawver sold 50,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $11.10, for a total value of $555,000.00. Following the completion of the sale, the director now owns 210,346 shares of the company’s stock, valued at $2,334,840.60. This represents a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders sold 149,600 shares of company stock valued at $1,726,516. Insiders own 40.10% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on SPRY. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners upped their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Raymond James upped their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 14th. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Finally, Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, ARS Pharmaceuticals has an average rating of “Buy” and a consensus price target of $31.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.